Ligand binding assays (LBA) are analytical procedures to quantify an analyte (macromolecule) based on its affinity for a ligand, including but not limited to antibodies, antigens, receptors, oligonucleotides and peptides.

Scope of the Report:
The global Ligand Binding Assay market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Ligand Binding Assay.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Ligand Binding Assay market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Ligand Binding Assay market by product type and applications/end industries.

Market Segment by Companies, this report covers
Sygnature Discovery
Shanghai Medicilon Inc
Intertek Group plc
PerkinElmer Inc
Charles River
Alliance Pharma
Eurofins Discovery
Creative Biogene
IBR Inc
LGC Limited
Accelero Bioanalytics GmbH
Gifford Bioscience Limited
GE Healthcare
Antigen Discovery Inc

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Radioactive
Non-radioactive

Market Segment by Applications, can be divided into
Biomedical Research
Drug Discovery
Others